LY255283

LY255283 is a LTB4 receptor (BLT2) antagonist, with an IC50 of ~100 nM for [3H]LTB4 binding to guinea pig lung membranes[1][2][3][4].

Product Specifications

CAS Number

[117690-79-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Leukotriene Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ly255283.html

Purity

98.04

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C1=CC(CC)=C(OCCCCCC(C2=NNN=N2)(C)C)C=C1O)=O

Molecular Formula

C19H28N4O3

Molecular Weight

360.45

Precautions

H302, H315, H319, H335

References & Citations

[1]R M Schultz, et al. Effects of two leukotriene B4 (LTB4) receptor antagonists (LY255283 and SC-41930) on LTB4-induced human neutrophil adhesion and superoxide production. Prostaglandins Leukot Essent Fatty Acids. 1991 Aug;43 (4) :267-71.|[2]S A Silbaugh, et al. Pulmonary actions of LY255283, a leukotriene B4 receptor antagonist. Eur J Pharmacol. 1992 Nov 13;223 (1) :57-64.|[3]P S Wollert, et al. LY255283, a novel leukotriene B4 receptor antagonist, limits activation of neutrophils and prevents acute lung injury induced by endotoxin in pigs. Surgery. 1993 Aug;114 (2) :191-8.|[4]Eun-Young Kim, et al. BLT2 promotes the invasion and metastasis of aggressive bladder cancer cells through a reactive oxygen species-linked pathway. Free Radic Biol Med. 2010 Sep 15;49 (6) :1072-81.